A Proportional Hazards Model for the Subdistribution of a Competing Risk

Jason P. Fine

Journal of the American Statistical Association

PrognosisRare Event EstimationRisk MetricRisk AnalysisEmerging Risk +19

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf, +17

New England Journal of Medicine

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

Gregory Y.H. Lip, Robby Nieuwlaat, Ron Pisters, +2

CHEST Journal

ThrombosisVenous ThrombosisCardiovascular EpidemiologyIschemic StrokeCardiovascular Disease +12

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Paulus Kirchhof, Stefano Benussi, Dipak Kotecha, +47

EP Europace

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Paulus Kirchhof, Stefano Benussi, Dipak Kotecha, +47

European Heart Journal

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples

Peter C. Austin

Statistics in Medicine

Propensity ScoreHealth PolicyMatching TechniqueMedicinePharmacoepidemiology +12

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Robert P. Giugliano, Christian T. Ruff, Eugene Braunwald, +17

New England Journal of Medicine

Validation of Clinical Classification Schemes for Predicting Stroke

Brian F. Gage, Amy D. Waterman, William D. Shannon, +3

JAMA

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study

Renate B. Schnabel, Xiaoyan Yin, Philimon Gona, +12

The Lancet

ThrombosisCardiovascular EpidemiologyHealth PolicyCardiovascular DiseaseAtrial Fibrillation Prevalence +11

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Lars Wallentin, Salim Yusuf, Michael D. Ezekowitz, +11

The Lancet

ThrombosisVenous ThrombosisCardiovascular DiseaseStrokeRe-ly Trial +11